Investing.com — ARS Pharmaceuticals’ stock experienced a significant rise, peaking at an 11% increase, marking the largest intraday leap since August.
This surge was prompted by the company’s announcement of its preliminary fourth-quarter net revenue for its allergy spray, Neffy, which surpassed analyst predictions.
The preliminary net product revenue for Neffy in the fourth quarter was approximately $6.5 million. This figure significantly outperformed the average estimate of $3.11 million projected by analysts, as surveyed by Bloomberg.
In 2024, the total net product sales amounted to around $7.1 million. This revenue was generated after the allergy spray became accessible to wholesalers and pharmacies on September 23.
Looking ahead to 2025, ARS Pharmaceuticals has indicated its intention to boost demand and gain more traction among its target prescribers.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
